Serna Bio

Serna Bio, previously known as Ladder Therapeutics (LTX), operates primarily in the healthcare industry with a focus on therapeutics. The company is engaged in the development of innovative therapeutics that target the transcriptome, aiming to address globally relevant diseases that currently lack adequate treatments. With a small team of two, Serna Bio maintains operations in Ontario, CA, USA, and London, England, UK, and also supports fully remote positions. This early-stage biotech company was part of the Y Combinator W21 batch and actively operates across various regions including the United States, United Kingdom, America/Canada, and Europe. Serna Bio’s work is crucial in the fields of biotech and drug discovery.